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Abstract  
BACKGROUND: Allogeneic hematopoietic stem cells transplantation (HSCT) is a curative intervention in patients 
with haematological malignant and non-malignant diseases, immunodeficiency, autoimmune, and other genetic 
diseases. Early complications are complications that are occurring in the first 100 days, while complications 
arising after the 100th day of transplantation belong to late complications.
 
CASE REPORT: Forty-nine years old patient with AML treated with allogeneic HSCT from HLA-identical (sister) 
donor. Ascertained and display of early (acute Graft versus host disease (GvHD) and late complications (chronic 
GVHD, infections, cataract, secondary malignancy with MS deposits) are made, that emerged after the patient 
transplantation. 
 
CONCLUSION: Rapidly growing population of patients that undergo allogeneic HSCT creates an obligation to 
educate patients and physicians about observed late complications that occur after this therapy. 
 
 
 
 
 
 
 
 
Introduction 
 
Allogeneic hematopoietic stem cells 
transplantation (HSCT) represent a curative modality 
for the treatment of patients with haematological 
malignant and non-malignant diseases, 
immunodeficiency, autoimmune, and other genetic 
diseases [1]. The risk and the type of complications 
depend on actions of preparation before the 
transplantation [2], the age of the patient [3], time of 
allogeneic transplantation, the present comorbid 
conditions and some other prognostic parameters [4-
6] which are subject to current clinical studies [7-10]. 
Relapse of the underlying primary disease and graft 
versus host disease (GvHD) [11] are leading causes 
of death, and in patients who survived five years or 
more after allogeneic HSCT the quality of life is almost 
normal [12]. Leading causes of sudden death are 
secondary malignancy [13], recurrent disease 
followed by infections, chronic GvHD, respiratory and 
cardiovascular diseases. Late complications are now 
more challenging in patients who underwent HSCT 
[14], particularly those who were transplanted before 
35 years [15, 16]. 
Early complications - complications that 
occur in the first 100 days are haemorrhagic cystitis 
[17]; veno-occlusive disease (VOD);  thrombotic 
microangiopathy [18]; upper respiratory complications. 
Infections (bacterial, viral [19] and fungal 
infections) - Immune reconstitution has a key role in 
preventing long-term complications after allogeneic 
HSCT [20, 21]. The infection is thought to be early if 
it’s diagnosed < 40 days after allo-transplantation, late 
if it’s diagnosed 40-100 days and very late if it’s 
diagnosed >100 days after allogeneic transplantation 
[22]. 
 
Graft-versus-host-disease (GvHD) [11, 23]
  
Acute GvHD - In the early period (first 100 
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days) after transplantation, acute GVHD develops in 
25%-75% of patients, targeting the skin, liver and 
gastrointestinal tract. Acute GVHD is classified 
according to the severity and number of organs 
involved, from grade I-IV, with grade IV that has the 
highest mortality rate. 
Chronic GvHD - Chronic GVHD is the most 
common and serious late complication of HSCT. 
Depending on the type of onset, chronic GVHD can 
develop directly from acute GvHD (progressive) - 
which has a poor prognosis, or it can follow a period 
of resolution (inactive). Finally, patients may develop 
chronic GVHD with no history of previous acute GvHD 
(de-novo) [24]. 
Gastrointestinal tract is frequently involved 
and a major cause of morbidity and mortality after 
transplantation. Changes in liver enzymes occur up to 
80% in patients with allogeneic HSCT. Acute form 
manifests 2-10 weeks after transplantation. Liver 
involvement in chronic GVHD is the most common 
cause of late liver disease. 
 
Late complications 
Delayed post-transplant complications occur 
after day 100. At this time, the recovery of cellular 
immunity is complete, while the recovery of the 
humoral immunity may take several years [21]: Eye 
complications - cataracts, "sicca" syndrome; 
cardiovascular [14, 25] - arterial hypertension, 
cardiomyopathy, arrhythmia [26, 27]; respiratory - 
COPD, obstructive bronchiolitis; hepatic - chronic 
GvHD of liver, liver cirrhosis, chronic hepatitis; renal – 
nephropathy; skeletal - avascular necrosis, 
osteoporosis; oral - chronic stomatitis, late dental 
infections; endocrine [25] - hormone imbalances, 
diabetes, infertility [28], premature menopause; 
neurological - leukoencephalopathy, peripheral 
neuropathy; most common complications during this 
period are chronic GvHD, secondary malignancies 
[13] and relapse [29]. 
 
 
Case Report 
 
A 34-year-old patient was hospitalised for the 
first time at the University Clinic of Hematology in 
Skopje on June 2001 due to pronounced weakness, 
fatigue, heart palpitations, loss of weight, prolonged 
genital bleeding and occurrence of purpura on 
extremities. The patient denied the medical history of 
diseases. The physical examination notes 
undernutrition without present lymphadenopathy and 
organomegaly, skin and visible mucous membranes 
were coloured pale with signs of the hemorrhagic 
syndrome on limb skin in the form of purpura. Patient 
haematological parameters were in addition to 
anaemic syndrome (Hb 78 g/L) with marked 
thrombocytopenia (Tr 35 x 10
9
 L). Biochemical 
analysis was in normal range except LDH that was 
above the limit values (LDH 434 U/l). Microbiology 
with findings of Streptococcus pneumonia in sputum 
and Enterococcus in urine, for what appropriate 
antibiotic therapy was ordinate. Sternal Puncture 
showed hypocellularity of the bone brain with 
infiltration of > 80% blasts in peripheral smear with 
morphological and cytochemical characteristics of 
myeloblasts, a finding that fits in addition to acute 
myeloid leukaemia (AML). A chemotherapy according 
to DAE protocol was started, and included - dau 
oblast in, ARA-C and VePesid (M2) and other 
supportive therapy. Due to the appearance of febrile 
conditions and hemorrhagic syndrome, blood products 
and immunoglobulins were administered. The control 
of sternal puncture showed blasts of around 50-60%. 
The treatment continued with additional two cycles of 
chemotherapy (DAE protocol), without achieving 
complete remission. On November 2001 the patient 
was hospitalised at the Clinic of Haematology to 
undergo allogeneic HSCT from HLA-identical sibling 
(sister) donor. Due to the present febrile episodes, 
another cycle of chemotherapy was conducted - DAE 
protocol (where daunorubicin was replaced with 
idarubicin) after what the allogeneic HSCT was 
realised. The conditioning regiment for HSCT 
consisted of Bu-Cy protocol that includes - Busulfan 
and Cyclophosphamide. The post-transplant period 
was spent properly. Supportive therapy and antibiotics 
were ordinate empirically, blood products and 
treatment for GvHD prophylaxis were performed on 
day -1 with Cyclosporin A and Methotrexate.  
 
Figure 1: Lung CT Figure 2 – Abdominal CT (left lower lobe mass - 
metastasis) (large lesion, with characteristics indicative of 
metastasis) 
 
On day +17 the presence of acute GvHD 
grade, I-II on skin was noted, which is additionally 
treated with corticosteroid therapy. In the following 
hospitalisation in the period of 3-4 years, the 
emergence of "sicca" syndrome, tachycardia, 
occasional loose stools and skin erythema with 
elevated transaminase activity was noted - signs of 
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chronic GvHD as a late complication for what is 
ordinate appropriate immunosuppressive and 
corticosteroid therapy. 
 
Figure 2: Abdominal CT (large lesion, with characteristics indicative 
of metastasis) 
 
On several occasions after transplantation, 
there has been an outbreak of pneumonia with 
subsequent febrile episodes due to incomplete 
immune reconstitution for what the patient is treated 
with parenteral antibiotic therapy and 
immunoglobulins. The controls in the daily hospital 
were neat, and regular therapy was ordinate. Another 
late complication resulting from transplantation also 
occurred - subsequent cataract which was operatively 
determined in October 2010. Fourteen years after 
transplantation the patient complains of difficulty in 
breathing, swallowing and cough. Because of this 
signs gastroscopy was made, pathophysiology was 
taken from the mycosis infiltration, and oesophagal 
cancer was diagnosed. Surgical intervention was 
conducted in August 2014. The control that followed in 
April 2015, on the abdominal ultrasound were 
detected MS deposit in the liver; chest X-ray showed 
Tu formation for what an additional CT was preformed 
- that confirmed the MS deposits (Figures 1 & 2). 
Another surgical intervention in May 2015 was 
conducted, the ith lethal outcome in November 2015, 
due to the progression of secondary cancer with 
metastatic deposits in the liver, lungs and bones 
(T2H1M1 classification). 
Regarding the underlying disease – AML, the 
patient was in complete haematological remission in 
the past period
 
 
 
Discussion 
 
Allogeneic HSCT is a curative treatment for 
many haematological malignant and non-malignant 
diseases and other diseases that provide recovery 
and expected long lifespan [1, 3, 4, 15]. Complications 
occur due to the highly aggressive chemotherapy and 
disorders of the immune system [10, 21, 22]. Our case 
report was about 49 years old patient, who was 
diagnosed with AML, first treated with chemotherapy 
according to DAE protocol, then after achieving 
hematologic remission, an allogeneic HSCT was 
made from HLA-identical sibling donor. Acute GvHD 
on the skin grade I-II as an early complication after 
allogeneic transplantation was noted and 
appropriately treated with additional corticosteroid 
therapy, despite the given prophylactic therapy. In the 
years after the transplantation, the patient had 
frequent occurrences of infections and chronic GVHD 
due to incomplete immune reconstitution which was 
appropriately treated with immunoglobulins, 
corticosteroids, antibiotics and other supportive 
therapy. Fourteen years after the transplantation, a 
secondary malignancy was noted - cancer of the 
esophagus, with MS deposits in lungs, liver and bones 
as a late complication after which lethal outcome 
happened. Chronic GVHD [11] remains a major 
challenge - a risk factor [23, 24]. The rapidly growing 
population of patients that undergo allogeneic HSCT 
creates an obligation to educate patients and 
physicians about observed late complications that 
occur after this therapy [8, 12]. 
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